RECRUITINGEarly Phase 1INTERVENTIONAL
Effect of Captopril on GLS in Duchenne Myodystrophy
Intermediate Term Effect of Captopril on Left Ventricle Global Longitudinal Strain in Patients With Duchenne Myodystrophy
About This Trial
To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD)
Who May Be Eligible (Plain English)
Who May Qualify:
- Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS \< -18% with minimum age of 6 years old.
Who Should NOT Join This Trial:
- Any patient who refuses to sign an willing to sign a consent form.
- Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
- Reduced ejection fraction below 50%.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS \< -18% with minimum age of 6 years old.
Exclusion Criteria:
* Any patient who refuses to sign an informed consent.
* Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
* Reduced ejection fraction below 50%.
Treatments Being Tested
DRUG
Captopril Tablets
Patients will be given captopril to see effect on global longitudinal strain
Locations (1)
Ain Shams university
Cairo, Egypt